Evidence map›Paper›PMID 11598028›Full record

ArticleInfection and immunity2001

Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein.

C Jespersgaard, P Zhang, G Hajishengallis, M W Russell, S M Michalek

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

C JespersgaardDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
P Zhang
G Hajishengallis
M W Russell
S M Michalek
University of Alabama at Birmingham · US

Funding

Genetically Engineered Oral Vaccines &Caries ImmunityR01DE009081 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MICHALEK, SUZANNE M. · 1990 to 2012
$3.2M
ANTIGENS OF STREPTOCOCCUS MUTANS IN CARIES IMMUNITYR37DE006746 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RUSSELL, MICHAEL W · 1999 to 2008
$2.4M
REGULATION OF IMMUNE RESPONSES IN THE ORAL CAVITYR01DE008182 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MICHALEK, SUZANNE M. · 1988 to 2003
$972k
PROTEIN ANTIGENS OF STREP MUTANS IN CARIES IMMUNITYR01DE006746 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RUSSELL, MICHAEL W · 1985 to 1998
–
NIDCR NIH HHS DE06746NIDCR NIH HHS DE08182NIDCR NIH HHS DE09081NIDCR NIH HHS R01 DE008182NIDCR NIH HHS R01 DE009081NIDCR NIH HHS R37 DE006746
6 · The paper itself

Abstract

Attenuated Salmonella enterica serovar Typhimurium has been used for targeted delivery of recombinant antigens to gut- and nose-associated lymphoid tissues. Contradictory reports have described the effect of preexisting immunity to the antigen delivery vehicle. We decided to examine this discrepancy by studying the effect of immunizing mice by the intranasal (i.n.) route with Salmonella expressing an insoluble protein and to study the ability to augment recall responses by boosting with either Salmonella-expressed protein or purified soluble protein alone. The glucan-binding domain (GLU) of the enzyme glucosyltransferase (GTF), which is an important virulence factor of Streptococcus mutans, was recombinantly expressed in the insoluble phase in S. enterica serovar Typhimurium, and the immunogenicity of this construct was studied in mice. We examined the induction of primary immune responses by insoluble GLU polypeptide delivered in Salmonella at week 1 (groups 1 and 2) and recall responses after a week 15 boost with either Salmonella expressing GLU (group 1) or purified GLU polypeptide (groups 2 and 3). Group 4 served as the control and received phosphate-buffered saline alone by the i.n. route. Significant anti-GLU serum immunoglobulin G (IgG) levels were seen in groups 1, 2, and 3 at week 18 (P < 0.001), i.e., 3 weeks after the booster immunization. Mice in group 2, who received Salmonella followed by GLU, had the highest GLU-specific IgG levels among all groups. The serum IgG levels persisted in all responding groups for at least 7 weeks after the boost (week 22). The IgG2a/IgG1 subclass ratio of serum anti-GLU antibodies in group 1 significantly increased after the boost. These results support the induction of a type 1-like immune response to GLU after primary and booster immunizations with Salmonella expressing GLU. On the other hand, group 2 mice, which received Salmonella expressing GLU as the primary dose and soluble protein as the booster dose, exhibited a shift from a type 1-like to a more type 2-like immune response to GLU following the boost. These results indicate that S. enterica serovar Typhimurium is an excellent delivery vehicle for the insoluble and recombinantly expressed GLU of GTF and that this construct was especially effective in priming the host for a secondary response to soluble GLU polypeptide.

Indexed as

Genetic VectorsSalmonella typhimuriumAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsCarrier ProteinsFemaleGene ExpressionGlucosyltransferasesImmunoglobulin AImmunoglobulin GLectinsMiceMice, Inbred BALB CProteinsAntibodies, BacterialAntigens, BacterialBacterial ProteinsCarrier Proteinsglucan-binding proteinsglucosyltransferase IGlucosyltransferasesGTF-I protein, StreptococcusImmunoglobulin AImmunoglobulin GLectinsProteins

Identifiers

PMID11598028
PMCPMC100033
OpenAlexW2103716124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.